NESINA Drug Profile, 2023

This report focuses on NESINA and covers the following critical aspects of this drug:

• United States patents
• Expired United States patents
• FDA Paragraph IV patent challenges
• District Court patent litigation
• European supplementary protection certificates (SPCs)
• Clinical trials
• Drug prices
• Finished product suppliers
• Raw active pharmaceutical ingredient (API) sources

OSENI Drug Profile, 2023

This report focuses on OSENI and covers the following critical aspects of this drug:

• United States patents
• Expired United States patents
• District Court patent litigation
• European supplementary protection certificates (SPCs)
• Drug prices
• Finished product suppliers
• Raw active pharmaceutical ingredient (API) sources

EDURANT Drug Profile, 2023

This report focuses on EDURANT and covers the following critical aspects of this drug:

• United States patents
• Expired United States patents
• District Court patent litigation
• European supplementary protection certificates (SPCs)
• Clinical trials
• Drug prices
• Finished product suppliers
• Raw active pharmaceutical ingredient (API) sources

KAZANO Drug Profile, 2023

This report focuses on KAZANO and covers the following critical aspects of this drug:

• United States patents
• Expired United States patents
• FDA Paragraph IV patent challenges
• District Court patent litigation
• European supplementary protection certificates (SPCs)
• Clinical trials
• Drug prices
• Finished product suppliers

Diabetes mellitus affects approximately 20 million people in the US, or nearly 7% of the population. It is expected to increase by 70% within the next 25 years, and numerous epidemiologic studies have demonstrated that type 2 diabetes increases the risk of cardiovascular morbidity and mortality. It is estimated to cost over $92 billion in health care costs and lost productivity. The increased risk is due to the detrimental vascular effects of prolonged exposure to a hyperglycemic, oxidant-rich environment yielding associated cardiovascular risk factors: atherosclerosis, hypertension and clotting abnormalities. Hypertension and dyslipidemia in diabetic patients produces substantial decreases in cardiovascular and microvascular diseases. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome provides an overview of the current epidemic, outlines the consequences of this crisis and lays out strategies to forestall and prevent diabetes, obesity and other intricate issues of metabolic syndrome. The contributing experts from around the world give this book relevant and up-to-date global approaches to the critical consequences of metabolic syndrome and make it an important reference for those working with the treatment, evaluation or public health planning for the effects of metabolic syndrome and diabetes. Scientific discussion of the epidemiology and pathophysiology of the relationship between diabetes and metabolic syndrome Includes coverage of Pre-diabetes conditions plus both Type I and Type II Diabetes Presents both prevention and treatment options

Medicinal Foods as Potential Therapies for Type-2 Diabetes and Associated Diseases: The Chemical and Pharmacological Basis of their Action focuses on active pharmacological principles that modulate diabetes, associated risk factors, complications and the mechanism of action of widely used anti-diabetic herbal plants—rather than just the nutritional composition of certain foods. The book provides up-to-date information on acclaimed antidiabetic super fruits, spices and other food ingredients. Sections cover diabetes and obesity at the global level, the physiological control of carbohydrate and lipid metabolism, the pathophysiology of type-2 diabetes, the chemistry and pharmacology of a variety of spices, and much more. This book will be invaluable for research scientists and students in the medical and pharmaceutical sciences, medicinal chemistry, herbal medicine, drug discovery/development, nutrition science, and for herbal practitioners and those from the nutraceutical and pharm industries. - Provides background knowledge on type-2 diabetes and its pathophysiology and therapeutic targets down to the molecular level - Explores, in detail, the chemistry or secondary metabolites of the indicated foods that potentially modify diabetes and/or associated diseases - Examines the pharmacological findings on medicinal foods, including available clinical trials

The incidence of diabetes is increasing at epidemic proportions worldwide, presenting a huge challenge to modern medicine. In response, scientific advances in the understanding of diabetes and its complications are being translated into improved clinical practice at ever faster rates. Greater understanding of aetiopathogenesis of the different types of diabetes, the emerging roles of novel pharmacological agents and the importance placed on multidisciplinary team working and multi-risk-factor treatment all contribute to this. Now in a fully revised second edition, this clear, concise guide to modern diabetes and its management will prove invaluable to all health professionals in this field. Suitable for instant reference in the clinic or office. Helps answer the questions which diabetic patients will direct at their carers about their disease, its causes, prognosis and consequences for their lifestyle. Offers practical and accessible advice on all aspects of the condition from presentation and diagnosis to organisation of care. Suitable for diabetic nurses as well as junior doctors. Evidence based boxes give the rationale behind treatment decisions. Colour illustrations of important conditions such as diabetic retinopathy and foot disease. Key points highlighted throughout the book, vital/high risk points emphasized with exclamation mark icon. More information on insulin therapy, dyslipidaemia, macrovascular disease and hypertension. Complete rewrite of oral antidiabetic agents section. Smaller, more pocketable page size.